Digestive Diseases and Sciences

, Volume 60, Issue 7, pp 2077–2087 | Cite as

Aspirin Has a Protective Effect Against Adverse Outcomes in Patients with Nonvariceal Upper Gastrointestinal Bleeding

  • Antonios Wehbeh
  • Hani M. Tamim
  • Hussein Abu Daya
  • Rachel Abou Mrad
  • Rami J. Badreddine
  • Mohamad A. Eloubeidi
  • Don C. Rockey
  • Kassem Barada
Original Article



To determine the effect of aspirin and anticoagulants on clinical outcomes and cause of in-hospital death in patients with nonvariceal upper gastrointestinal bleeding (NVUGIB).


Patients were identified from a tertiary center database that included all patients with UGIB. Clinical outcomes including (1) in-hospital mortality, (2) severe bleeding, (3) rebleeding, (4) in-hospital complications, and (5) length of hospital stay were examined in patients taking (a) aspirin only, (b) anticoagulants only, and (c) no antithrombotics.


Of 717 patients with NVUGIB, 56 % (402) were taking at least one antithrombotic agent. Seventy-eight (11 %) patients died in hospital, and 310 (43 %) had severe bleeding (BP < 90 mmHg, HR > 120 b/min, Hb < 7 g/dL on presentation, or transfusion of >3 units). On multivariate analysis, being on aspirin was protective against in-hospital mortality [OR 0.26 (0.13–0.53)], rebleeding [OR 0.31 (0.17–0.59)], and predictive of a shorter hospital stay (coefficient = −4.2 days; 95 % CI −8.7, 0.3). Similarly, being on nonaspirin antiplatelets was protective against in-hospital mortality (P = 0.03). However, being on anticoagulants was predictive of in-hospital complications [OR 2.0 (1.20–3.35)] and severe bleeding [OR 1.69 (1.02–2.82)]. Compared to those not taking any antithrombotics, patients who bled on aspirin were less likely to die in hospital of uncontrolled gastrointestinal bleeding (3.6 vs 0 %, P ≤ 0.01) and systemic cancer (4.9 vs 0 %, P ≤ 0.002), but equally likely to die of cardiovascular/thromboembolic disease, sepsis, and multiorgan failure.


Patients who present with NVUGIB on aspirin had reduced in-hospital mortality and fewer adverse outcomes, while those on anticoagulants had increased in-hospital complications.


Hemorrhage Aspirin Anticoagulant Outcome Morbidity Mortality 



Upper gastrointestinal bleeding


Nonvariceal upper gastrointestinal bleeding






Conflict of interest



  1. 1.
    British Society of Gastroenterology Endoscopy Committee. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut. 2002;51:iv1–iv6.Google Scholar
  2. 2.
    Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol. 2007;102:290–296.PubMedCrossRefGoogle Scholar
  3. 3.
    Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut. 2011;60:1327–1335.PubMedCrossRefGoogle Scholar
  4. 4.
    van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: Did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98:1494–1499.PubMedCrossRefGoogle Scholar
  5. 5.
    Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414–1419.PubMedCrossRefGoogle Scholar
  6. 6.
    Theocharis GJ, Thomopoulos KC, Sakellaropoulos G, Katsakoulis E, Nikolopoulou V. Changing trends in the epidemiology and clinical outcome of acute upper gastrointestinal bleeding in a defined geographical area in Greece. J Clin Gastroenterol. 2008;42:128–133.PubMedCrossRefGoogle Scholar
  7. 7.
    Laine L. Review article: gastrointestinal bleeding with low-dose aspirin—What’s the risk? Aliment Pharmacol Ther. 2006;24:897–908.PubMedCrossRefGoogle Scholar
  8. 8.
    Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract. 2012;66:53–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108–1115.PubMedCrossRefGoogle Scholar
  10. 10.
    Abraham NS, Hartman C, Richardson P, Castillo D, Street RL Jr, Naik AD. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. Circulation. 2013;128:1869–1877.PubMedCrossRefGoogle Scholar
  11. 11.
    Boonpongmanee S, Fleischer DE, Pezzullo JC, et al. The frequency of peptic ulcer as a cause of upper-GI bleeding is exaggerated. Gastrointest Endosc. 2004;59:788–794.PubMedCrossRefGoogle Scholar
  12. 12.
    Ahsberg K, Hoglund P, Stael von Holstein C. Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther. 2010;32:801–810.PubMedCrossRefGoogle Scholar
  13. 13.
    Lanas A, Aabakken L, Fonseca J, et al. Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europe. Aliment Pharmacol Ther. 2011;33:1225–1233.PubMedCrossRefGoogle Scholar
  14. 14.
    Sostres C, Lanas A. Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding? Drugs. 2011;71:1–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014;113:662–668.PubMedCrossRefGoogle Scholar
  17. 17.
    Mose H, Larsen M, Riis A, Johnsen SP, Thomsen RW, Sorensen HT. Thirty-day mortality after peptic ulcer bleeding in hospitalized patients receiving low-dose aspirin at time of admission. Am J Geriatr Pharmacother. 2006;4:244–250.PubMedCrossRefGoogle Scholar
  18. 18.
    Ortiz V, Ortuno J, Rodriguez-Soler M, Iborra M, Garrigues V, Ponce J. Outcome of non-variceal acute upper gastrointestinal bleeding in patients with antithrombotic therapy. Digestion. 2009;80:89–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Clinical outcome in upper gastrointestinal bleeding complicating low-dose aspirin and antithrombotic drugs. Aliment Pharmacol Ther. 2006;24:633–636.PubMedCrossRefGoogle Scholar
  20. 20.
    Abu Daya H, Eloubeidi M, Tamim H, et al. Opposing effects of aspirin and anticoagulants on morbidity and mortality in patients with upper gastrointestinal bleeding. J Dig Dis. 2014;15:283–292.PubMedCrossRefGoogle Scholar
  21. 21.
    Rotondano G, Cipolletta L, Koch M, et al. Predictors of favourable outcome in non-variceal upper gastrointestinal bleeding: implications for early discharge? Dig Liver Dis. 2014;46:231–236.PubMedCrossRefGoogle Scholar
  22. 22.
    Sung JJ, Tsoi KK, Ma TK, Yung MY, Lau JY, Chiu PW. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol. 2010;105:84–89.PubMedCrossRefGoogle Scholar
  23. 23.
    Marmo R, Koch M, Cipolletta L, et al. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED Score and Prospective Comparison with the Rockall Score. Am J Gastroenterol. 2010;105:1284–1291.PubMedCrossRefGoogle Scholar
  24. 24.
    Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–2224.PubMedCrossRefGoogle Scholar
  25. 25.
    Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Hreinsson JP, Kalaitzakis E, Gudmundsson S, Bjornsson ES. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand J Gastroenterol. 2013;48:439–447.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology. 2013;144:1384–1393, 1393 e1381–1382; quiz e1318–1389.Google Scholar
  28. 28.
    Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–113.PubMedCrossRefGoogle Scholar
  29. 29.
    Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I. Should more patients continue aspirin therapy perioperatively? Clinical impact of aspirin withdrawal syndrome. Ann Surg. 2012;255:811–819.PubMedCrossRefGoogle Scholar
  30. 30.
    John BK, Arramraju S, Shalomov A, Sison C, Rubin M. Antiplatelet agents do not impact the hospital course in patients with gastrointestinal bleeding. J Clin Gastroenterol. 2011;45:583–589.PubMedCrossRefGoogle Scholar
  31. 31.
    Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut. 1994;35:464–466.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Ahsberg K, Hoglund P, Kim WH, von Holstein CS. Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol. 2010;45:1404–1415.PubMedCrossRefGoogle Scholar
  33. 33.
    Thomopoulos KC, Mimidis KP, Theocharis GJ, Gatopoulou AG, Kartalis GN, Nikolopoulou VN. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World J Gastroenterol. 2005;11:1365–1368.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Chiu PW, Joeng HK, Choi CL, Kwong KH, Ng EK, Lam SH. Predictors of peptic ulcer rebleeding after scheduled second endoscopy: clinical or endoscopic factors? Endoscopy. 2006;38:726–729.PubMedCrossRefGoogle Scholar
  35. 35.
    Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med. 1994;331:717–727.PubMedCrossRefGoogle Scholar
  36. 36.
    Elmunzer BJ, Young SD, Inadomi JM, Schoenfeld P, Laine L. Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol. 2008;103:2625–2632; quiz 2633.Google Scholar
  37. 37.
    Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology. 2009;137:525–531.PubMedCrossRefGoogle Scholar
  38. 38.
    Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc. 2003;58:369–373.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Antonios Wehbeh
    • 1
  • Hani M. Tamim
    • 2
  • Hussein Abu Daya
    • 3
  • Rachel Abou Mrad
    • 1
  • Rami J. Badreddine
    • 1
  • Mohamad A. Eloubeidi
    • 1
  • Don C. Rockey
    • 4
  • Kassem Barada
    • 1
  1. 1.Division of Gastroenterology and HepatologyAmerican University of Beirut Medical CenterBeirutLebanon
  2. 2.Biostatistics Support Unit, Clinical Research InstituteAmerican University of Beirut Medical CenterBeirutLebanon
  3. 3.Department of Internal MedicineUniversity of Pittsburgh Medical CenterPittsburghUSA
  4. 4.Department of Internal MedicineThe Medical University of South CarolinaCharlestonUSA

Personalised recommendations